Yahoo
NasdaqCM - Delayed Quote USD

NeuroOne Medical Technologies Corporation (NMTC)

0.8790 +0.0179 (+2.08%)
At close: November 6 at 4:00:01 PM EST
Chart Range Bar
Loading chart for NMTC
  • Previous Close 0.8611
  • Open 0.8800
  • Bid 0.9500 x 600
  • Ask 1.3800 x 300
  • Day's Range 0.8489 - 0.8849
  • 52 Week Range 0.7720 - 6.1200
  • Volume 27,328
  • Avg. Volume 342,676
  • Market Cap (intraday) 8.004M
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) --
  • EPS (TTM) -0.9900
  • Earnings Date (est.) Dec 15, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 7.27
  • Moby Rating Neutral

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.

nmtc1.com

18

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NMTC
80.67%
S&P 500 (^GSPC)
7.76%

1-Year Return

NMTC
79.62%
S&P 500 (^GSPC)
9.77%

3-Year Return

NMTC
84.09%
S&P 500 (^GSPC)
68.96%

5-Year Return

NMTC
94.77%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 2.89M
Earnings -1.44M
Profit Margin -49.71%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-2M
-1M
0
1M
2M
-160.0%
-140.0%
-120.0%
-100.0%
-80.0%
-60.0%

Analyst Insights

View More

Analyst Price Targets

5.00
7.27 Average
0.8790 Current
8.80 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst Maxim Group
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 13 -> 5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -59.71%

  • Return on Assets (ttm)

    -58.07%

  • Return on Equity (ttm)

    -124.66%

  • Revenue (ttm)

    12.47M

  • Net Income Avi to Common (ttm)

    -7.45M

  • Diluted EPS (ttm)

    -0.9900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.05M

  • Total Debt/Equity (mrq)

    4.65%

  • Levered Free Cash Flow (ttm)

    -4.57M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: